Ginkgo Bioworks Enhances Sequencing with Callisto Integration
Ginkgo Bioworks Integrates Callisto for Enhanced NGS Processes
Ginkgo Bioworks, a leader in cell programming and biosecurity, has taken a significant step forward by integrating the Callisto™ Sample Prep System into their high-throughput laboratory environment. This collaboration aims to refine and optimize Illumina sequencing workflows, paving the way for advancements in genomics.
Innovative Solutions for High Throughput Labs
At the forefront of genomic applications, Ginkgo Bioworks emphasizes the importance of innovative solutions in handling complex sequencing processes. The integration of Callisto reflects their commitment to harnessing technology that streamlines workflows, particularly for steps that are notoriously difficult to automate, such as the preparation of PacBio libraries and the meticulous double-sided size selection required for Illumina sequencing.
Advancements in Sequencing Technology
In a statement, Alex Plocik, Senior Director of Genomics at Ginkgo Bioworks, shared his enthusiasm about the capabilities of Callisto. He noted, "I like the Apps and the App Store concept on Callisto. It allows us to keep our operating costs low and access multiple sequencing technologies and chemistries on the same platform. In our short-read sequencing workflow, we often pool thousands of individual samples into tens of sample pools for bead cleanups, varying batch sizes daily. Callisto is perfect for this scenario, providing a complete walk-away experience." This flexibility is essential as it allows Ginkgo to meet the evolving demands of genomic research without overspending on operational costs.
Partnerships Driving Innovation
Partnerships in the industry are vital for innovation. Udayan Umapathi, the founder and CEO of Volta Labs, remarked on the long-standing relationship with Ginkgo Bioworks. "Ginkgo has been a valued partner for Volta Labs since our inception," he stated. Udayan highlighted how Ginkgo’s feedback has been instrumental in refining Volta's solutions tailored for high throughput labs. He expressed excitement about the immediate integration of Callisto into their workflows, hinting at the vast potential for long-term applications.
New Features and Capabilities
Among the latest offerings is the newly released Size Selection app in the Volta Apps menu, which empowers labs utilizing various platforms like Illumina and Ultima Genomics. This app enhances the process of purification and optimal fragment size selection for sequencing. Despite technological advancements, tasks as basic yet essential as DNA cleanup remain challenging to automate with traditional liquid handling systems. Callisto’s sophisticated features, including electrowetting, magnetic, and acoustic technologies, provide precise liquid separation and efficient DNA elution from beads. Customers can now order kits for the Double-Sided Size Selection app on Callisto, making this advanced integration easily accessible.
About Volta Labs and Ginkgo Bioworks
Volta Labs stands out as a pioneering genomics applications company focused on revolutionizing the way biological research is conducted. Their cutting-edge digital fluidics platform optimizes scalability and performance in sample preparation, ensuring consistency in lab processes. Volta Labs has a mission to allow scientists to concentrate on pushing biological boundaries rather than getting bogged down by the technical aspects of their work.
Ginkgo Bioworks is recognized as a leading platform in the realm of cell programming. Their innovative approach addresses challenges in diverse markets, including food, agriculture, pharmaceuticals, and biosecurity. With ongoing efforts to develop technologies that can predict, detect, and respond to biological threats, Ginkgo continues to be at the forefront of the biotechnology industry.
Frequently Asked Questions
What is Ginkgo Bioworks known for?
Ginkgo Bioworks is renowned for its strategic focus on cell programming, offering versatile solutions across diverse sectors including pharmaceuticals and agriculture.
Why is the Callisto Sample Prep System significant?
The Callisto system is significant because it simplifies the automation of complex genomic processes, enhancing efficiency and reducing operating costs in laboratories.
How does Ginkgo Bioworks utilize technology?
Ginkgo Bioworks utilizes technology to streamline workflows in genomic research, allowing scientists to focus on innovation rather than labor-intensive tasks.
What recent advancements have been made in sequencing technology?
Recent advancements include the integration of the Size Selection app, which improves the purification and selection of DNA fragments specifically for sequencing.
How does the partnership between Ginkgo Bioworks and Volta Labs benefit research?
The partnership leverages innovative solutions and expertise from both companies, accelerating the development of robust sequencing workflows that can adapt to changing research needs.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
